Quest Diagnostics (DGX) has been making significant strides in many areas. Among the notable developments is the introduction of a
Human Papillomavirus specimen self-collection for cervical cancer screening. The company has consistently increased its dividend, with the latest hike bringing it to $0.80. Promising 2025 financial results are anticipated for Q1, around the same time DGX will pay its larger dividend.
Adrienne Brott has been appointed senior vice president and chief quality and regulatory affairs officer. DGX is also pursuing an aggressive growth strategy, with double-digit expansion planned in five areas. The company has finalized acquisitions of University Hospitals’ outreach lab services business and
LifeLabs. A remarkable tie-up with
Google Cloud AI has been announced for revolutionizing lab testing. DGX has made it to the Fortune's World's Most Admired Companies list for 11 consecutive years and is recognized as a leader in healthcare ranking. The company aims to streamline data and personalize customer experiences through
Generative AI in collaboration with Google Cloud. DGX will be taking control of certain lab assets from
Allina Health and
PathAI Diagnostics. Overall, DGX has shown strong momentum and an aggressive approach towards a new phase of growth and expansion.
Quest Diagnostics DGX News Analytics from Wed, 01 May 2024 07:00:00 GMT to Sat, 05 Apr 2025 00:52:47 GMT -
Rating 5
- Innovation 8
- Information 7
- Rumor 2
